Irhythm Holdings, Inc. current report, 06 October 2021

Business Context and Reporting Period

This Form 8-K Current Report was filed by iRhythm Technologies, Inc. on October 12, 2021, covering events reported as of October 6, 2021. The filing addresses significant changes to the Company's Board of Directors and committee structures, effective November 1, 2021.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

  • Resignation of Director: Raymond W. Scott resigned from the Board of Directors, the Audit Committee, and the Nominating and Corporate Governance Committee (where he served as chairperson). His resignation is not due to any disagreement with the Company.
  • Election of New Director: Karen Ling was elected as a Class I director to fill the vacancy created by Mr. Scott's resignation. The Board determined Ms. Ling is an independent director.
  • Committee Reassignments:
    • Audit Committee: Mark J. Rubash (chair), Renee Budig, and Ralph Snyderman, M.D.
    • Compensation Committee: Bruce G. Bodaken (chair), C. Noel Bairey Merz, M.D., Karen Ling, and Abhijit Y. Talwalkar.
    • Nominating and Corporate Governance Committee: Abhijit Y. Talwalkar (chair), Bruce G. Bodaken, and Mark Rubash.

Guidance, Outlook, and Management Commentary

The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that Ms. Ling's compensation will be consistent with other non-employee directors, subject to proration. The text confirms there are no arrangements or understandings regarding Ms. Ling's appointment and no family relationships with existing directors or officers.

Key Facts for Investor Verification

  • Verify the effective date of the Board changes is November 1, 2021.
  • Confirm Karen Ling's independence status and background (former EVP/CHRO at AIG and Allergan).
  • Review the updated composition of the Audit, Compensation, and Nominating and Governance Committees.
  • Note that the resignation of Raymond W. Scott was not due to any disagreement with the Company.